The Engineering and Physical Research Sciences Council (EPRSC) at UK Research and Innovation (UKRI) has awarded researchers at Imperial College London with a £5.5 million ($7.07 million) grant to develop a non-invasive technology that monitors the activity of individual brain cells. The grant was awarded by the…
News
Although Parkinson’s disease (PD) is largely known for tremor and other motor symptoms, the vast majority of patients in an informal survey said they noticed non-motor issues, such as cognitive changes, first. The one-question Facebook survey, conducted by the medical device company PhotoPharmics, was reported to draw more…
Orthostatic hypotension, a sudden drop in blood pressure when changing positions, can significantly affect both function and quality of life for people with Parkinson’s disease. However, this non-motor symptom — typically attributed to later disease stages — is not associated with an increased risk of Parkinson’s and…
The International Linked Clinical Trials (iLCT) program, a collaborative effort from The Cure Parkinson’s Trust (CPT), the Van Andel Institute (VAI), and now the John Black Charitable Foundation (JBCF), has pledged $6.75 million over three years to support clinical trials of potential Parkinson’s disease treatments.
The Aligning Science Across Parkinson’s initiative has awarded a $6 million grant to a research team looking to define the molecular connections between aging and Parkinson’s disease. The three-year grant, issued by the Michael J. Fox…
Scientists have developed a new system that can provide a controlled and sustained release of parkinsonian medications, thus enabling better management of Parkinson’s disease. The mechanisms behind this delivery system were described in the study, “Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson’s Disease,” published in the…
Seelos Therapeutics has signed an agreement with Duke University in North Carolina to conduct a pre-clinical study of SLS-004, one of its gene therapy candidates, as a treatment for Parkinson’s disease. The proof-of-concept study will seek to determine if the investigational therapy can prevent or delay Parkinson’s disease…
Simvastatin, a widely-used cholesterol-lowering medication, failed to slow the progression of Parkinson’s disease, according to data from a Phase 2 trial. Based on these findings, it was decided that a future Phase 3 study assessing the safety and efficacy of simvastatin in these patients would not be…
The Aligning Science Across Parkinson’s (ASAP) initiative has awarded a $7.2 million grant to a research team working to unravel the structure and biology of leucine-rich repeat kinase 2 (LRRK2), a protein linked to familial Parkinson’s disease. The three-year grant, issued by the Michael J. Fox Foundation (MJFF), was…
Reduced protein synthesis could serve as a biomarker to help diagnose Parkinson’s disease, even before motor symptoms appear, a recent study suggests. The study, “Protein synthesis is suppressed in sporadic and familial Parkinson’s disease by LRRK2,” was published in The FASEB Journal. The LRRK2 protein (leucine-rich repeat…
Recent Posts
- Being reminded that my uncle was still in the room was an important lesson
- MJFF grant funds expansion of trial testing NEU-411 in Parkinson’s
- Medication, symptoms top concerns of Parkinson’s community: Survey
- Happy 65th, Michael J. Fox! A Parkinson’s patient’s crush lives on.
- Scenic joins LITE program to test Parkinson’s treatment approach